Tesamorelin VAT Reduction Stack
Risk: ModerateClinical-grade visceral adipose reduction — tesamorelin is the only peptide with FDA approval for VAT reduction, and ipamorelin amplifies the GH pulse without disturbing cortisol. The combo targets stubborn abdominal fat while preserving lean mass and improving lipid profile.
Composition: 2 GH & IGF Axis
Overview
The Tesamorelin VAT Reduction Stack is purpose-built for users who want measurable, clinical-grade reduction of visceral adipose tissue (VAT)—the deep, hard-to-shift fat that isn't just cosmetic but closely tied to metabolic health risks. Tesamorelin is the only peptide with FDA-validated VAT reduction data in humans, and stacking it with ipamorelin amplifies growth hormone release for a synergistic effect without unwanted cortisol or hunger spikes. This is not a general fat-loss or beach-cut protocol—it's for users who want targeted visceral fat reduction, preservation of lean tissue and improved lipid markers, whether that's to resolve GH gut, cut NAFLD risk, or achieve a tighter midsection after cycles that add deep fat.
Why this stack works
- Tesamorelin: The core VAT-cutting tool—drives potent, pulse-style growth hormone release via GHRH axis signaling. Directly validated for visceral and hepatic fat loss by MRI in phase 3 studies. Prefers deep/organ fat rather than subQ, so you don't end up with a 'gaunt' look while fixing the real problem. Dose is set at 2 mg SC daily for maximal efficacy, as this is the studied ceiling with a very clear dose-response above 1 mg.
- Ipamorelin: Amplifies the GH pulse from tesamorelin by acting through the ghrelin (GHSR) pathway, stacking GHRH and GHRP for a non-linear GH/IGF-1 response. Chosen over GHRP-2/6 as it's cleaner (no inappropriate prolactin/cortisol spike, minimal bloating, no severe hunger). The combo increases VAT mobilization efficiency and preserves lean mass—while staying well within a 'physiologic' range that doesn't suppress natural axis function post-cycle.
- Synergy: By pairing a GHRH analog (tesamorelin) with a GHRP (ipamorelin), you unlock a potentiated pituitary GH output each day. Both have a minimal side effect footprint compared to GH itself, with less water retention, no suppression, and lower risk of IGF-1 spikes that drive insulin sensitivity issues.
Protocol timeline
1 phase · 16 weeks total
Timeline shows the 16-week cycle. Bars overlap when phases run concurrently. Click a bar to jump to its detail card.
Cycle starts
2025
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2027
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
| Week | Compound | Dose | Frequency | Notes |
|---|---|---|---|---|
| 1-16 | Tesamorelin | 2 mg | Once daily SC | AM, fasted (preferably same time each day) |
| 1-16 | Ipamorelin | 300 mcg | Once daily SC | Stack in same syringe as tesamorelin if desired, also AM fasted |
- Both compounds are pinned subcutaneously (abdomen works well; rotate sites).
- AM fasted dosing is favored for synergy and to mimic physiologic GH pulse, but pre-bed is also viable especially if sleep/recovery is a focus. Pick one timing and be consistent.
- Monitor blood glucose: Tesamorelin can transiently worsen glucose tolerance. Check fasting glucose at baseline, then every 4 weeks. If trending up, consider low-dose berberine or metformin as an adjunct.
- IGF-1 tracking: Run labs at baseline, week 8, and week 16. If IGF-1 climbs above upper reference, consider titrating to every-other-day ipamorelin.
- Water and sodium: Mild water retention is expected. Keep sodium stable; avoid wild swings.
- Nocturnal cortisol risk: If you find AM dosing of ipamorelin disrupts sleep or feel 'wired' later in the day, move both pins to pre-bed.
- GH/peptide antagonists: Absolutely avoid exogenous GH within this window (counterproductive, blunts pituitary response). No concurrent GHRP-2/6 or CJC-1295.
- Supplement stack: If running metformin/berberine or lipid modulating compounds, stagger those at least 6+ hours away from peptide dosing to avoid potential interference with GH pulse.
Compounds in this stack
2 linked · tap for full guide
How they work together
Multipliers applied to the projection above when these compounds run together. Values > 1 indicate a bonus, < 1 a penalty.
| Pair | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.12 | ×1.23 | ×1.10 |
Cycle outcome projection
Projection across all phases (16 weeks total) using the same math as the stack-calculator tool. Adjust gender, cycle length, and goal to see how the numbers move.
Body Transformation Preview
Lean Mass Gain
2.1 lbs
1.6–2.6 lbs range
Fat Loss
6.9 lbs
5.2–8.6 lbs range
Lean Synergy Bonus
+12%
from compound pairing
Fat Loss Synergy
+23%
from compound pairing
Per-Compound Contribution
Fat Loss by Week
Where to buy
Swiss Chems
Affiliate link — we may earn a commission at no cost to you.
- Tesamorelin· Buy Tesamorelin, 2mg - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy Tesamorelin
- Ipamorelin· Buy Ipamorelin 2 mg - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy Ipamorelin
Real Peptides
Affiliate link — we may earn a commission at no cost to you.
- Tesamorelin· Tesamorelin 10mgBuy Tesamorelin
- Ipamorelin· IpamorelinBuy Ipamorelin
Conclusion
If stubborn visceral fat is your bottleneck—whether it's GH gut, NAFLD, or just that last slab of belly you can't shift—this stack is the most proven, clinical-tier approach. Prepare to monitor IGF-1, glucose, and body composition monthly. When ready, follow the dosing to the letter and stay ahead of any metabolic drift. Visceral fat melts when the protocol's dialed in.
Updated 2026-04-19